Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals
Mycopathologia · 2024
DOI: 10.1007/s11046-024-00869-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycopathologia, 2024. Verfasst von Bram Spruijtenburg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radboudumc-CWZ Center of Expertise for Mycology, Weg Door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Antifungal Agents, Microbial Sensitivity Tests, Aspergillus, Aspergillosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The genus Aspergillus consists of a vast number of medically and environmentally relevant species. Aspergillus species classified in series Versicolores are ubiquitous in the environment and include the opportunistic pathogen Aspergillus sydowii , which is associated with onychomycosis and superficial skin infections. Despite frequent clinical reports of A. sydowii and related series Versicolores species, antifungal susceptibility data are scarce, hampering optimal treatment choices and subsequent patient outcomes. Here, we employed antifungal susceptibility testing (AFST) based on microbroth dilution on a set of 155 series Versicolores strains using the common antifungals amphotericin B, itraconazole, voriconazole, posaconazole, isavuconazole and micafungin with the addition of luliconazole and olorofim. All strains were identified using partial calmodulin gene sequencing, with 145 being A. sydowii, seven A. creber and three A. versicolor , using the latest taxonomic insights. Overall, tested antifungals were potent against the entire strain collection. In comparison to A. fumigatus , azole and amphotericin B MICs were slightly elevated for some strains. AFST with luliconazole and olorofim, here reported for the first time, displayed the highest in vitro activity, making these antifungals interesting alternative drugs but clinical studies are warranted for future therapeutic use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radboudumc-CWZ Center of Expertise for Mycology, Weg Door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands.
- Canisius-Wilhelmina Hospital (CWZ)/Dicoon, 6532 SZ, Nijmegen, The Netherlands.
- Servicio de Microbiología, Hospital Universitario Miguel Servet, IIS Aragon, Saragossa, Spain.
- Westerdijk Fungal Biodiversity Institute, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.
- Institute for Biodiversity and Ecosystems Dynamics, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Zitieren
APA
Spruijtenburg, B., Rezusta, A., Houbraken, J., Hagen, F., de Groot, T., Meis, J. F., & Meijer, E. F. J. (2024). Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals. Mycopathologia. https://doi.org/10.1007/s11046-024-00869-8
Vancouver
Spruijtenburg B, Rezusta A, Houbraken J, Hagen F, de Groot T, Meis JF, et al. Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals. Mycopathologia. 2024. doi:10.1007/s11046-024-00869-8
BibTeX
@article{Spruijtenburg2024,
author = {Spruijtenburg, Bram and Rezusta, Antonio and Houbraken, Jos and Hagen, Ferry and de Groot, Theun and Meis, Jacques F and Meijer, Eelco F J},
title = {Susceptibility Testing of Environmental and Clinical Aspergillus sydowii Demonstrates Potent Activity of Various Antifungals},
journal = {Mycopathologia},
year = {2024},
doi = {10.1007/s11046-024-00869-8}
}
EUVIMED